We’re fearless in the fight against vision loss on behalf of the more than 5 million people globally who live with #GeographicAtrophy (GA), which leads to progressive and irreversible vision loss. Attending #ASRS2024? Learn more about how to support your patients living with GA at booth 411. #WeAreApellis
Apellis Pharmaceuticals
Biotechnology Research
Waltham, MA 69,747 followers
Global biopharma company leveraging courageous science, creativity, and compassion to deliver life-changing therapies.
About us
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8
- Website
-
https://apellis.com/
External link for Apellis Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Waltham, MA
- Type
- Public Company
- Founded
- 2008
- Specialties
- Targeted C3 Therapies, Complement System, Hematology, Ophthalmology, Nephrology, Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy (GA), C3 Glomerulopathy (C3G), Cold Agglutinin Disease (CAD), Gene Therapy, Neurology, and Amyotrophic Lateral Sclerosis (ALS)
Locations
-
Primary
100 Fifth Ave
3rd Floor
Waltham, MA 02451, US
-
720 Market Street
5th Floor
San Francisco, California 94102, US
-
Zählerweg 10
Zug, 6300, CH
Employees at Apellis Pharmaceuticals
-
Beth Marsh
Commercial Strategy and Launch | Sales Management | Business Development | Training & Development
-
Alexandre de Jesus
Associate Director @ Apellis Pharmaceuticals | Commercial Operations Excellence
-
Renaud Desgraz, PhD
-
Lisa Paul-Stark
Patient focused rare disease medical sales professional with over 20 years of success, including more than 18 years in rare/Orphan disease, focusing…
Updates
-
Hello from Sweden! 👋 Attending #ASRS2024? Come meet the team and learn more about our work in #GeographicAtrophy (GA) at booth #411. #WeAreApellis
-
In case you missed it – we’re looking forward to sharing data that reinforce the robust efficacy and well-documented safety profile of our #GeographicAtrophy (GA) treatment at #ASRS2024 this week. Get the details on the 6 abstracts, including 5 oral presentations: https://bit.ly/3XVMthv
-
We deeply care about the needs of people living with debilitating retinal diseases. We're proud to support Prevent Blindness in their mission to reduce barriers to care and advance meaningful policy, research and programs in eye health. #WeAreApellis
Many thanks to the Gold Sponsors of the 13th Annual Prevent Blindness Focus on Eye Health Summit, starting at 11 a.m. ET! Amgen, Apellis Pharmaceuticals, BIO (Biotechnology Innovation Organization) and Regeneron . It's not too late to register! Just go to https://lnkd.in/ecCZxf9d #EyeSummit
-
We’re excited to share that 6 abstracts, including 5 oral presentations, will be presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting July 17 - 20 in Stockholm, Sweeden: https://bit.ly/3XVMthv These data include a late-breaking presentation showing our #GeographicAtrophy (GA) treatment demonstrated visual function benefit on prespecified endpoint in the GALE long-term extension study. #ASRS2024
-
Today, we shared a regulatory update on the review of our investigational treatment for geographic atrophy in the European Union. Learn more: https://bit.ly/45G0nGB
-
What a night! We joined the BrightFocus Foundation last night for Concert For Cures, which supports patients living with retina diseases. Thank you BrightFocus Foundation for a night of hope, innovation and music! #WeAreApellis
-
The challenge is on. We’re looking for an #ApellisEyeQ champion - check out this week’s poll! #WeAreApellis
This content isn’t available here
Access this content and more in the LinkedIn app
-
We strive to understand the unique challenges people with rare diseases face and are committed to always putting patients first. We take pride in supporting patients like Ashley, who is living with #PNH, a rare and potentially life-threatening blood disease. Learn more about our commitment to the rare disease community: https://bit.ly/4baXFv2 #WeAreApellis
-
At Apellis, each of our values guide every decision we make as we strive toward our vision of being known for our compassion, revolutionary science, and contributions to humankind around the world. #WeAreApellis Learn more about our culture: https://lnkd.in/ezckD-Ns